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Context: Individuals with the functional ER22/23EK variant in the
glucocorticoid receptor gene are relatively resistant to the down-
stream consequences of glucocorticoids. Evidence suggests that car-
riers have a more favorable cardiovascular risk profile, but the rela-
tionship between this ER22/23EK variant and cardiovascular disease
has not been hitherto assessed.
Objective: We, therefore, determined whether carriership of the
ER22/23EK improves cardiovascular disease risk in patients with
severe hypercholesterolemia.
Design, Setting, and Participants: In a multicenter cohort study,
2024 patients with heterozygous familial hypercholesterolemia, aged
18 yr and older, were genotyped for the ER22/23EK polymorphism.
Patients were identified at lipid clinics throughout The Netherlands
between 1989 and 2002.
Main Outcome Measures: The primary outcome measure was car-
diovascular disease.
Results:Seventy-six (7.8%) of 977men and 72 (6.9%) of 1047womenwere
carriers of theER22/23EKvariant. A total of 395men and 247womenhad
a cardiovascular event. In contrast to expected results, we observed no
significant association of the ER22/23EK variant with cardiovascular dis-
ease risk (men: relative risk, 0.75; 95% confidence interval, 0.50–1.14; P
0.2;women: relative risk, 1.37; 95%confidence interval, 0.82–2.28;P0.2).
However, we found a significant interaction between gender and the poly-
morphism on cardiovascular disease (P  0.02).
Conclusions: In this large cohort of individuals with very high risk
of cardiovascular disease, the association between the functional
ER22/23EK polymorphism and cardiovascular risk was not signifi-
cant overall, although it varied significantly by gender. (J Clin En-
docrinol Metab 91: 4131–4136, 2006)
FAMILIAL HYPERCHOLESTEROLEMIA (FH) is an au-tosomal dominant disorder caused by mutations in the
low-density lipoprotein (LDL) receptor gene (1). The prev-
alence of heterozygotes in Caucasian populations averages
about 1:500, positioning FH among the most common mo-
nogenetic disorders in man (2). Patients with FH have se-
verely increased LDL cholesterol levels and a pronounced
susceptibility to premature cardiovascular disease (CVD) (1,
2). Despite themonogenetic nature of this disorder, however,
large variation in CVD risk is observed (3, 4). Age, gender,
smoking, body mass index (BMI), and the presence of hy-
pertension and diabetes mellitus contribute to this variation
of CVD risk (5, 6). In addition, polymorphisms in candidate
genes have also been shown to modulate the expression of
the clinical phenotype (7–15), supporting the concept that the
hereditary component of CVD is determined by multiple
genes, each explaining only a limited proportion of the risk
(16). The present challenge is to identify those markers that
improve risk prediction in FH to tailor preventive strategies
to the individual risk level.
Variants in the glucocorticoid receptor gene have been
associated with a plethora of cardiovascular risk factors (17).
One of these variants consists of two linked, single-nucle-
otide changes in codons 22 and 23 of exon 2. The mutation
in codon 22 at nucleotide position 198 does not result in an
amino acid change [both coding for a glutamic acid (E)],
whereas the other sequence change in codon 23 at nucleotide
position 200 causes a change from arginine (R) to lysine (K).
Therefore, this variant has been named ER22/23EK. Upon
dexamethasone suppression testing, carriers of the ER22/
23EK variant express higher serum cortisol concentrations as
well as a smaller decrease in cortisol levels, suggesting a
relative resistance to glucocorticoids (18). Recently, the
pathophysiological basis of this resistance was elucidated
(19, 20). Alternative translation initiation occurs that results
in two isoforms of the glucocorticoid receptor: a long (GR-A)
and a short (GR-B) isoform (21). The GR-B protein has stron-
ger gene transcription-activating effects (20). The ER22/
23EK polymorphism affects translation, resulting in a shift
toward the less active GR-A variant (19, 20). In fact, associ-
ation studies have shown that carriers have 1) lower plasma
total and LDL cholesterol levels, 2) increased insulin sensi-
tivity, 3) beneficial body composition, and 4) lower plasma
C-reactive protein levels and a better survival (18, 22, 23).
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These findings suggest that carriers of this functional
ER22/23EK variant in the glucocorticoid receptor gene may
have a reduced risk of CVD. Nevertheless, this relationship
has not been assessed. In the present study, we therefore
investigated the effect of this polymorphism on CVD in pa-
tients heterozygous for FH.
Patients and Methods
Study design and study population
Between 1989 and 2002, lipid clinics throughout The Netherlands
submitted blood samples of 9300 patients who were clinically suspected
for FH to a central laboratory for LDL receptormutation analysis (6). Out
of this database, we randomly selected 4000 patients and diagnosed FH
according to previously published criteria (6).We excluded subjectswith
secondary causes of hypercholesterolemia and those with hypercholes-
terolemia caused by other genetic defects, such as familial defective
apolipoprotein B. A total of 2400 unrelated patients aged 18 yr and older
fulfilled the diagnostic criteria for heterozygous FH. Over 99% of these
patients were Caucasian. The institutional review board of each partic-
ipating hospital approved the study protocol, and informed consentwas
obtained from all patients.
Data collection
Patients’medical recordswere used to acquire information about age,
gender, smoking, BMI, and the presence of hypertension (patients with
a documented diagnosis using antihypertensivemedication or a systolic
blood pressure 140 mmHg or a diastolic blood pressure 90 mmHg
at three consecutive office visits) and diabetes mellitus (patients using
antidiabetic medication or fasting plasma glucose  6.9 mmol/liter).
Additional information was sought from general practitioners and hos-
pitals that patients had visited formerly and with questionnaires to
ensure data completeness.
Lipid levels were determined in fasting patients not using lipid-
lowering medication for at least 6 wk. Total cholesterol, high-density
lipoprotein (HDL) cholesterol, and triglycerides weremeasured by stan-
dard methods. LDL cholesterol was calculated with the Friedewald
formula. Forty patients had triglyceride levelsmore than 4.5mmol/liter,
and in these individuals LDL cholesterol concentrations were directly
measured by standard methods.
CVD and coronary heart disease (CHD) definitions
CVD was defined as coronary, cerebral, or peripheral artery disease
using internationally accepted criteria as published before (6). CHDwas
defined by the presence of 1) myocardial infarction, 2) percutaneous
coronary intervention or other invasive procedures, 3) coronary artery
bypass grafting, or 4) angina pectoris.
Molecular analysis
DNA was available from 2024 heterozygous FH patients for the
present analyses. Genomic DNA was extracted from peripheral blood
leukocytes according to a standard protocol (24). The ER22/23EK poly-
morphism in the glucocorticoid receptor gene was detected by allelic
discrimination using TaqMan Universal PCR master mix (Applied Bio-
systems, Foster City, CA), primers (forward, 5-AGAAGAAAAC-
CCCAGCAGTGT-3, and reverse, 5-CAGTAGCTCCTCCTCT-
TAGGGTTTTA-3), probes (Applied Biosystems), and a TaqMan ABI
Prism 7900 Sequence Detection System (Applied Biosystems). The
probes used were 5-FAM-CACATCTCCCTTTTCCTGA-3 and 5-VIC-
CACATCTCCCCTCTCCTGA-3 (Applied Biosystems). Reaction com-
ponents and amplification parameterswere based on themanufacturer’s
instructions using an annealing temperature of 60 C.
Statistical analysis
All data were analyzed using SPSS for Windows software package
version 11.5.0 (SPSS Inc., Chicago, IL). Because the hormone dynamics
and the risk of CVD differ considerably between men and women, we
stratified our analyses by gender. As expected, the number of ER22/
23EK homozygotes was limited; the analyses of heterozygous and ho-
mozygous carriers were therefore combined. Contingency tables were
used with 2 tests to compare observed genotype frequencies with those
expected under Hardy-Weinberg equilibrium. Differences between
ER22/23EK carriers and noncarriers and men and women were tested
with 2 statistics for dichotomous variables or independent-sample t test
for continuous variables. Statistical testing of triglyceride levels was
performed after logarithmic transformation. We used multiple logistic
regression analysis to adjust statistical tests for age.
The association between the ER22/23EK polymorphism and the oc-
currence of CVD and CHD was evaluated using a Cox proportional
hazard regression analysis. The proportional hazards assumption was
tested by drawing log minus log plots of the survival function and was
met for all Cox proportional hazard models. Follow-up started at birth
and ended at the first occurrence of established fatal or nonfatal CVD.
Patients without CVD were censored at the date of the last lipid clinic
visit or at the date of death attributable to causes other than CVD. In the
primary model, we adjusted for year of birth and smoking. Additional
variables, which had significant effects on CVD risk in univariate Cox
regression analyses, were investigated in the secondary model. Young
patients with the polymorphismmay not have had the chance to express
their high CVD risk. Hence, inclusion of young carriers of the poly-
morphismmay cause underestimation of CVD risk. Therefore, we tested
the effect of age by adjusting for age tertiles in the Cox regression
analysis. The interaction between the ER22/23EK variant and gender in
the total populationwas statistically tested in theCox regression analysis
with adjustment for variables that were significantly different between
genders. Throughout, a two-tailed P value of  0.05 was interpreted as
statistically significant.
Results
Patient characteristics
In 977 men heterozygous for FH, 76 (7.8%) individuals
were heterozygous for the ER22/23EK polymorphism, but
no homozygous carriers were detected. In 1047 women het-
erozygous for FH, 70 (6.7%)were heterozygous for the ER22/
23EK variant whereas two (0.2%) were homozygous. In
women with CVD, the ER22/23EK variant deviated from
Hardy-Weinberg equilibrium (2 9.182; P 0.002) because
of the small number of homozygotes; omitting one of them
resulted in equilibrium. The genotype distributions in the
total cohort and in all other subgroups (Table 1) did not differ
from Hardy-Weinberg equilibrium (2  1.610; P  0.2).
The clinical and biochemical characteristics of carriers and
noncarriers of the ER22/23EK polymorphism are presented
in Table 2. In men, no differences existed between patients
with andwithout ER22/23EK. Female carriers of ER22/23EK
were 4.6  1.7 (sd) yr younger at the first lipid clinic visit
compared with women without the polymorphism (P 
0.006). Other variables were not significantly different be-
tween female carriers and noncarriers.
Males visited the lipid clinic 2.3 0.6 (sem) yr earlier, were
more often smokers (difference, 12.0  2.1%), and had a
higher BMI (difference, 0.7 0.2 kg/m2), lower plasma LDL
cholesterol (difference, 0.24  0.09 mmol/liter) and HDL
cholesterol (difference, 0.23  0.02 mmol/liter) levels, and
higher plasma triglyceride concentrations (difference, 0.34
0.05 mmol/liter) compared with women, all as expected.
Risk factors for CVD
During 44,044 person-years, 395 (40.4%) men had onset of
CVD, and a total of 247 (23.6%) women had their first car-
diovascular event during 51,331 person-years. The mean age
4132 J Clin Endocrinol Metab, October 2006, 91(10):4131–4136 Koeijvoets et al. • Glucocorticoid Receptor Polymorphism and CVD in FH
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 13 August 2015. at 06:06 For personal use only. No other uses without permission. . All rights reserved.
of onset of CVD ( sd) was 45.7  9.3 yr in men and 52.8 
11.6 yr in women.
Separate analyses of a number of variables, which may act
as confounder or intermediate trait in the relationship be-
tween the ER22/23EK polymorphism and CVD risk, are
presented in Table 3. In men and women, year of birth,
smoking, and lower plasma HDL cholesterol concentrations
were significantly associated with increased CVD risk. The
presence of diabetesmellitus also contributed to an increased
risk of CVD in women but not in men. Hypertension, BMI,
plasma LDL cholesterol levels, and triglyceride concentra-
tionswere not significantly associatedwith CVD amongmen
or women.
CVD and the ER22/23EK polymorphism
In the total population,we found no significant association
between the ER22/23EK variant and CVD with adjustment
for year of birth, gender, and smoking [relative risk (RR) 0.92;
95% confidence interval (CI), 0.67–1.27; P 0.6). Unadjusted
survival rates of men and women with and without the
ER22/23EK polymorphism are shown in Table 4. Figure 1
illustrates the association between the ER22/23EK polymor-
phism and the cumulative incidence of CVD during lifetime
follow-up in patients with FH after adjustment for year of
birth and smoking and stratified by gender. The ER22/23EK
polymorphism was not significantly associated with CVD in
either gender;male carriers had a 0.75 (95%CI, 0.50–1.14;P
0.2) times decreased risk of CVD, whereas female carriers
had a 1.37 (95% CI, 0.82–2.28; P  0.2) times increased CVD
risk. As shown in Table 5, additional adjustment of plasma
HDL cholesterol concentrations in men and plasma HDL
cholesterol concentrations and diabetes mellitus in women
did not change the results. To test for effects of the ER22/
23EK variant on CVD riskwith age, we repeated themultiple
Cox regression analyses of the primary model with addi-
tional adjustment for age tertiles. After this additional ad-
justment, theCVD risk estimates remained virtually identical
in men (RR, 0.75; 95% CI, 0.49–1.13; P  0.2) and in women
(RR, 1.41; 95% CI, 0.84–2.35; P  0.2).
Although we found no significant relationship between
the ER22/23EK variant and CVD overall, the effect of the
polymorphism on CVD risk seemed opposite in men and
women. Therefore, we tested the interaction between the
ER22/23EK variant and gender in the total population using
Cox regression analysis with adjustment for variables that
were significantly different between genders (age, smoking,
BMI, and plasma LDL cholesterol, HDL cholesterol, and
triglyceride levels). Indeed, the effect of the ER22/23EK vari-
ant on CVD risk was significantly different for men and
women (P  0.02).
CHD and the ER22/23EK polymorphism
CHD was the most frequent cardiovascular event; in 350
men (88.6%) and 200 women (81.0%), CHD was the first
event. Cerebral artery disease occurred as the first event in
only 20 men (5.1%) and 20 women (8.1%); in 25 men (6.3%)
TABLE 2. Characteristics of male and female FH patients with and without the ER22/23EK polymorphism in the glucocorticoid
receptor gene
Men Women
Noncarriers
(n  901)
ER22/23EK carriers
(n  76)
P valuea Noncarriers
(n  975)
ER22/23EK carriers
(n  72)
P valuea
Age at first lipid clinic visit (yr) 43.6  0.4 43.3  1.2 0.8 46.2  0.4 41.5  1.6 0.006
Age at last lipid clinic visit (yr) 48.7  0.4 47.7  1.2 0.4 51.0  0.5 47.7  1.7 0.07
Smoking, ever (%) 79.3  1.4 76.1  5.1 0.6 67.7  1.6 57.6  6.1 0.08
Hypertension (%) 8.6  0.9 6.8  2.9 0.6 10.1  1.0 8.5  3.3 0.9
Diabetes mellitus (%) 5.5  0.8 3.9  2.2 0.7 6.3  0.8 6.9  3.0 0.6
BMI (kg/m2) 25.5  0.1 25.7  0.4 0.5 24.8  0.1 24.3  0.5 0.4
Total cholesterol (mmol/liter) 9.36  0.07 9.41  0.24 0.8 9.67  0.06 9.76  0.28 0.4
LDL cholesterol (mmol/liter) 7.24  0.07 7.22  0.26 0.9 7.46  0.07 7.70  0.27 0.2
HDL cholesterol (mmol/liter) 1.09  0.01 1.14  0.04 0.3 1.32  0.01 1.30  0.05 0.6
Triglycerides (mmol/liter) 1.96  0.03 2.15  0.11 0.4b 1.64  0.03 1.64  0.13 0.9b
Values are given as means SEM. SI conversion factors: to convert total cholesterol, LDL cholesterol, and HDL cholesterol to mg/dl, multiply
by 38.67; for triglycerides, multiply by 89.15.
a Additional adjustment for age.
b Statistical testing after logarithmic transformation.
TABLE 1. Genotype and allele frequencies for the ER22/23EK polymorphism in the glucocorticoid receptor gene
Men n (%) Women n (%)
CVD No CVD CVD No CVD
Genotypes
Wild type 368 (93.2) 533 (91.6) 231 (93.5) 744 (93.0)
Heterozygous ER22/23EK 27 (6.8) 49 (8.4) 14 (5.7) 56 (7.0)
Homozygous ER22/23EK 0 (0.0) 0 (0.0) 2 (0.8) 0 (0.0)
Total 395 (100.0) 582 (100.0) 247 (100.0) 800 (100.0)
Alleles
Wild type allele 763 (96.6) 1115 (95.8) 476 (96.4) 1544 (96.5)
ER22/23EK allele 27 (3.4) 49 (4.2) 18 (3.6) 56 (3.5)
Total 790 (100.0) 1164 (100.0) 494 (100.0) 1600 (100.0)
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and 27 women (10.9%), the first event was peripheral artery
disease.
In the total population, again we observed no significant
relationship between the polymorphism and CHD after ad-
justment for year of birth, gender, or smoking (RR, 0.93; 95%CI,
0.67–1.31;P 0.7).With adjustment for year of birth and smok-
ing, the ER22/23EK polymorphism was not significantly asso-
ciated with CHD in men (RR, 0.72; 95% CI, 0.46–1.12; P 0.1)
or women (RR, 1.60; 95% CI, 0.94–2.73; P  0.09). Adjustment
for additional variables resulted in similar risk estimates (Table
5). In linewith the results for CVD, the effect of the ER22/23EK
variant on CHD risk was significantly different between men
and women (P  0.006).
Discussion
We hypothesized that the functional ER22/23EK variant
in the glucocorticoid receptor genemight decrease CVD risk.
In this large cohort at severely increased risk, however, the
association between the ER22/23EK variant and the occur-
rence of CVD or CHD was not significant overall. Nonethe-
less, in a post hoc analysis, we found opposite effects of the
polymorphism on CVD and CHD in men and women.
Exogenous as well as endogenous glucocorticoid excess in
humans contributes to the development of hypertension,
dyslipidemia, impaired glucose tolerance, and central adi-
posity, and may alter thrombosis and fibrinolysis (25, 26).
Glucocorticoids exert their function primarily via binding to
the cytoplasmic glucocorticoid receptor,which then transfers
into the nucleus where it enhances or represses transcription
of specific target genes (27). The ER22/23EK polymorphism
in the glucocorticoid receptor gene results in a relative glu-
cocorticoid resistance and has been associated with a bene-
ficial cardiovascular risk profile defined by lower plasma
total andLDL cholesterol levels, increased insulin sensitivity,
and beneficial body composition (18, 21). In addition, carriers
had lower plasma C-reactive protein levels as well as better
overall survival (22). In our FH cohort, 7.3% of the individ-
uals carried at least one copy of the variant, in concordance
with genotype frequencies described in previous studies
(5.2–8.9%). In contrast to expected results, we found no sig-
nificant association between the ER22/23EK polymorphism
and CVD or CHD risk. The severe hypercholesterolemia in
our patients might offer a clue as to why we observe these
results. The potential beneficial effect of this polymorphism
may be partly a result of lower LDL cholesterol levels (18).
Wedid not observe, however, such differences; the dominant
dyslipidemia of FHmay outweigh potential beneficial effects
on cholesterol metabolism. In the general population, vari-
ants in the glucocorticoid receptor gene may be better risk
predictors for CVD. Alternatively, we made a type II error in
the separate analyses of men and women; differences were
not observed with statistical significance because of lack of
power because of small numbers. The results of our inter-
action analysis between the polymorphism and gender in the
total population support the latter alternative. Based on lit-
erature, we had a priori hypothesized that the ER22/23EK
variant decreased CVD risk, and the study was powered to
detect a significant association between the polymorphism
and cardiovascular risk in the total population.
Although we found no significant relationship between
the ER22/23EKpolymorphism andCVDorCHDoverall, the
influence of the genetic variant appears to be different be-
tween sexes. This variant has been preferentially analyzed in
male individuals, and most association studies did not an-
alyzemen andwomen separately. In a cohort of young adults
followed from the age of 13–36 yr, the body composition in
carriers of the ER22/23EK variant was indeed different be-
tween sexes; only male carriers were taller and leaner and
had more muscle strength (21). The reason for these differ-
ential effects of the ER22/23EK variant between men and
women is yet unknown. In rodents, the hypothalamic-pitu-
itary-adrenal axis responds to variations in circulating sex
TABLE 3. Risk factors of CVD in 977 men and 1047 women with familial hypercholesterolemia
Variables
Men Women
RR 95% CI P value RR 95% CI P value
Year of birth 1.05 1.04–1.07 0.001 1.08 1.06–1.10 0.001
Smoking 1.56 1.14–2.15 0.006 1.53 1.15–2.05 0.004
Diabetes mellitus 1.06 0.76–1.48 0.7 1.68 1.19–2.37 0.004
Hypertension 1.32 1.00–1.75 0.05 1.10 0.79–1.52 0.6
BMI 1.00 0.97–1.04 0.8 1.04 1.00–1.08 0.07
LDL cholesterol 0.99 0.92–1.06 0.7 1.00 0.93–1.08 0.9
HDL cholesterol 0.53 0.35–0.80 0.002 0.47 0.29–0.75 0.001
Triglycerides 1.15 0.99–1.35 0.08a 1.02 0.83–1.26 0.8a
a Statistical testing after logarithmic transformation.
TABLE 4. CVD-free survival of patients with familial hypercholesterolemia according to the ER22/23EK polymorphism in the
glucocorticoid receptor gene
Men Women
Noncarriers ER22/23EK carriers Noncarriers ER22/23EK carriers
CVD-free survivala
40 yr 62.9  1.9 63.0  6.5 87.1  1.3 85.7  5.2
50 yr 35.2  2.4 43.9  8.5 70.1  2.0 63.3  8.7
60 yr 20.5  2.9 31.4  12.2 49.2  2.8 41.0  11.8
Median survival time 54.7 56.8 69.6 66.0
a Cumulative CVD-free survival probability  SEM.
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steroid concentrations (28). This regulation differs between
sexes; estrogen primarily exerts stimulatory effects on stress-
induced ACTH and glucocorticoid release, whereas testos-
terone inhibits stress-related hypothalamic-pituitary-adre-
nal axis activity (28–30). As speculated previously, in a
relative glucocorticoid resistance condition, as is the case for
ER22/23EK carriers, the high circulating estrogen levels in
women may annul the potential beneficial effects of the
ER22/23EK variant (21). Otherwise, high variability in the
expression of genes located at the X chromosome between
men andwomen has been reported andmay also account for
these gender differences (31). An example of such a gene is
Mediator subunit MED14. Garabedian and co-workers (32,
33) found that MED14 interacts with the glucocorticoid re-
ceptor and increases its transcriptional activation in a gene-
specific manner. Interestingly, MED14 is X-linked and fails
to undergo X-chromosome inactivation. Therefore, the re-
searchers suggested that MED14 levels could be higher in
females than in males, which may represent a mechanism
underlying gender-specific differences in the expression of
glucocorticoid receptor target genes (33). These observations
support that separate analyses of men and women are in-
dicated for studies on the ER22/23EK variant.
The monogenetic background but large variation in CVD
risk determines the strength of the present study. Patients
with heterozygous FH have 8.5 times increased cardiovas-
cular risk (4). The atherosclerotic burden of the disorder,
however, exhibits wide variation, and many untreated FH
patients experience little or no excess mortality (3). As in the
general population, CVD in FH patients is the result of a
dynamic interplay amongmultiple genes in addition to gene-
environment interactions (3–5). The disorder is therefore
considered to be an exemplary model to analyze secondary
(or modifier) genes involved in CVD.
However, there are also some limitations to our association
study. It depended on medical records, questionnaires, and
information retrospectively obtained from physicians as the
primary source of data. Certain information of interest, such
as postmenopausal status, was not available. Furthermore,
the influence of the ER22/23EK polymorphism on potential
intermediate traits (e.g. dexamethasone suppression test, in-
sulin and C-reactive protein levels, body composition, and
FIG. 1. CVD hazard curve according to the ER22/23EK polymorphism in 977 men and 1047 women with heterozygous FH.
TABLE 5. Relative risks for CVD and CHD according to ER22/23EK genotype
Genotype
RR (95% CI)
Univariate Model 1 Model 2 Model 3
Men CVD
Wild type 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
ER22/23EK 0.86 (0.58–1.27) 0.75 (0.50–1.14) 0.73 (0.46–1.17) 0.75 (0.49–1.13)
Women CVD
Wild type 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
ER22/23EK 1.27 (0.76–2.10) 1.37 (0.82–2.28) 1.35 (0.74–2.44) 1.41 (0.84–2.35)
Men CHD
Wild type 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
ER22/23EK 0.83 (0.55–1.25) 0.72 (0.46–1.12) 0.72 (0.44–1.19) 0.71 (0.46–1.11)
Women CHD
Wild type 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
ER22/23EK 1.45 (0.86–2.45) 1.60 (0.94–2.73) 1.62 (0.86–3.02) 1.64 (0.96–2.80)
Model 1, adjusted for year of birth and smoking; model 2, adjusted for year of birth, smoking, andHDL cholesterol levels inmen, and adjusted
for year of birth, smoking, HDL cholesterol levels, and diabetes in women; model 3, adjusted for year of birth, smoking, and age tertiles.
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hormone levels) could not be determined. Our study in-
cluded patients that were referred to lipid clinics, and this
could lead to selection bias in two different ways. First,
patients with the most detrimental genetic profiles might
have died before referral, although we did not observe such
premature deaths in a previously reportedmortality analysis
(3). Nonetheless, we cannot exclude that polymorphisms
causing early death could have been missed, leading to un-
derestimation of the risk. Second, patients that presented
themselves with premature symptoms of atherosclerosis are
more easily referred to lipid clinics; this could lead to selec-
tion on CVD in our cohort study. However, we used data of
a nationwide screening program, and to prevent selection
biases,we selected only patients from the 48 larger outpatient
lipid clinics that are characterized by clinically more diverse
patient populations. Finally, our findings in heterozygous
FH cannot be extrapolated to other populations. The ob-
served opposite effects of the ER22/23EK variant on CVD
and CHD in our FH cohort should be validated or excluded
on wider population-based studies.
In conclusion, in this large, retrospective cohort study
among patients with heterozygous FH, the association be-
tween the functional ER22/23EK polymorphism and CVD
risk or CHD risk was not significant overall, although it
varied significantly by gender.
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